John Kenneth  Paglia net worth and biography

John Paglia Biography and Net Worth

Director of Simulations Plus
Dr. John K. Paglia is senior associate dean of academic affairs and professor of finance at Graziadio Business School. He previously served PGBS in a number of leadership roles over his eighteen year tenure at Pepperdine. He also served as associate dean for part-time (fully employed) programs, director of accreditation, chair of the accounting and finance department, and founding director of the Pepperdine Private Capital Markets Project.

A recognized expert on the topics of small business financing, business valuation, and financing and deal trends, Dr. Paglia has delivered over fifty presentations, including over a dozen keynote addresses, at key investment banking, private equity, accounting, small business, exit planning, and valuation events. He was also honored by the National Association of Certified Valuators and Analysts with the “Industry Titan” Award in 2016, the Alliance for Mergers & Acquisitions Advisors and Grant Thornton with a “Thought Leader of the Year Award” in 2012, and the Association for Corporate Growth with an “Excellence in M&A Award” in 2011. In 2016, he was also awarded with a consultancy contract with the Library of Congress Federal Research Division as a private equity and venture capital expert to conduct research on the economic impacts of the Small Business Administration’s Small Business Investment Company (SBIC) private equity program. His research has been covered in The Wall Street Journal, CNBC, USA Today, Businessweek, TIME, Bloomberg, Reuters, Inc., Forbes, Entrepreneur, MSNBC, ABC News, Huffington Post, Crain’s New York, The Los Angeles Times, The Washington Post, Financial Times, and The New York Times, among many others.

His research has been published in a number of journals including Journal of Banking and Finance, Journal of Entrepreneurial Finance, Journal of Accounting and Finance, Journal of Business Valuation and Economic Loss Analysis, Business Valuation Review, The Value Examiner, Journal of Wealth Management, The RMA Journal, Graziadio Business Review, and cited in Congressional testimony and SBA reports.

Dr. Paglia holds a PhD in finance, an MBA, a BS in finance, and is a Certified Public Accountant and Chartered Financial Analyst.

What is John Kenneth Paglia's net worth?

The estimated net worth of John Kenneth Paglia is at least $97,825.05 as of January 4th, 2024. Dr. Paglia owns 2,097 shares of Simulations Plus stock worth more than $97,825 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Paglia may own. Learn More about John Kenneth Paglia's net worth.

How do I contact John Kenneth Paglia?

The corporate mailing address for Dr. Paglia and other Simulations Plus executives is 42505 10TH STREET WEST, LANCASTER CA, 93534. Simulations Plus can also be reached via phone at (661) 723-7723 and via email at [email protected]. Learn More on John Kenneth Paglia's contact information.

Has John Kenneth Paglia been buying or selling shares of Simulations Plus?

John Kenneth Paglia has not been actively trading shares of Simulations Plus during the last quarter. Most recently, John Kenneth Paglia sold 1,000 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $43.74, for a transaction totalling $43,740.00. Following the completion of the sale, the director now directly owns 2,097 shares of the company's stock, valued at $91,722.78. Learn More on John Kenneth Paglia's trading history.

Who are Simulations Plus' active insiders?

Simulations Plus' insider roster includes John Paglia (Director), and Walter Woltosz (Director). Learn More on Simulations Plus' active insiders.

Are insiders buying or selling shares of Simulations Plus?

In the last year, insiders at the technology company sold shares 13 times. They sold a total of 177,744 shares worth more than $7,339,016.30. The most recent insider tranaction occured on April, 1st when Director Walter S Woltosz sold 20,000 shares worth more than $798,800.00. Insiders at Simulations Plus own 20.9% of the company. Learn More about insider trades at Simulations Plus.

Information on this page was last updated on 4/1/2024.

John Kenneth Paglia Insider Trading History at Simulations Plus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2024Sell1,000$43.74$43,740.002,097View SEC Filing Icon  
11/8/2023Sell1,000$35.25$35,250.003,097View SEC Filing Icon  
7/13/2023Sell1,200$46.45$55,740.002,644View SEC Filing Icon  
1/25/2022Sell600$40.76$24,456.00View SEC Filing Icon  
1/29/2021Sell13,260$79.25$1,050,855.00View SEC Filing Icon  
8/6/2019Sell690$37.86$26,123.402,112View SEC Filing Icon  
See Full Table

John Kenneth Paglia Buying and Selling Activity at Simulations Plus

This chart shows John Kenneth Paglia's buying and selling at Simulations Plus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Simulations Plus Company Overview

Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Read More

Today's Range

Now: $46.65
Low: $45.81
High: $46.85

50 Day Range

MA: $43.52
Low: $38.46
High: $50.73

2 Week Range

Now: $46.65
Low: $32.69
High: $52.69

Volume

103,593 shs

Average Volume

136,763 shs

Market Capitalization

$932.53 million

P/E Ratio

88.02

Dividend Yield

0.52%

Beta

0.72